Moderna: How mRNA became the software of life

Executive overview

Most drugs are one-offs — each one developed from scratch with no compounding advantage. Moderna bet on a platform: if mRNA can be delivered safely into cells, you only ever change the sequence, not the entire development process.

The COVID vaccine proved the platform works. Every drug after it inherits near-zero technical risk. The real question shifts from "can we make it?" to "does the biology respond?"

Once the delivery problem is solved, mRNA collapses drug development from years to weeks.

What mRNA actually does

• DNA is the cell's hard drive — the full genome stored as four chemical letters: A, T, C, G
• Messenger RNA (mRNA) is what the cell executes in real time — closer to RAM than storage
• Moderna's approach: inject synthetic mRNA directly, bypassing the DNA layer entirely
• The cell reads the foreign mRNA and produces whatever protein the sequence encodes
• A lipid nanoparticle (a tiny fat bubble) carries the mRNA past the immune system and into the cell
• The immune system must not recognise the mRNA as foreign — a chemical modification called silencing makes this work

Why the COVID vaccine was a turning point

• First-ever RNA vaccine approved and deployed at mass scale
• Sequence designed within days of the virus being identified; animal-model doses ready within weeks
• A traditional vaccine development timeline would have taken several years for the same steps
• 95% efficacy placed it alongside the Genentech insulin moment of 1978 — the start of a new drug category
• BioNTech achieved the same result but needed Pfizer to fund and distribute; Moderna did it alone, keeping 100% of economics

How Moderna was built differently

• Founded in 2010; stayed private longer than typical biotechs and scaled to a large organisation before IPO
• Most biotech startups pursue one drug; Moderna pursued a platform with 15+ clinical programs simultaneously
• Early deals with AstraZeneca and Alexion generated ~$300M upfront — enough to fund platform build-out without selling equity in every program
• Partnerships reserved rights in narrow verticals; Moderna kept all others for 100% owned drugs
• Scientists can type an mRNA sequence into software and receive a vial of drug within one to two weeks — an industrialised R&D loop no traditional pharma company had built

The platform advantage in drug economics

• Traditional drugs: technical risk is unique to each compound; success in one tells you little about the next
• mRNA drugs: once delivery and silencing are proven, the only variable between drugs is the sequence — technical risk collapses
• Moderna can test 100 different constructs for the same disease in the time a traditional process tests one or two
• COGS on the COVID vaccine: ~20% (typical for biologics); operating margin guided at ~50%
• R&D spend: the most expensive component is clinical trials, not scientists — "D is much more expensive than R"
• SG&A: selling to governments requires far fewer people than selling to thousands of doctors; marketing costs structurally lower

Pipeline and how investors evaluate it

• ~15 drugs in clinical development — a multiple of comparable-stage biotech companies
• Cytomegalovirus (CMV) vaccine: leading cause of birth defects in the US; no vaccine currently exists; potential multibillion-dollar market
• Rare disease protein-replacement: ~10,000 disorders where patients are missing a protein; mRNA just needs a new sequence for each; individual drugs may be small but the aggregate is large
• Investor framework: size the market, assign probability of success by stage, cut for biological risk (does the target actually drive disease?)
• Two distinct risk types: technical risk (does the drug behave as designed?) and biological risk (does fixing the target change patient outcomes?)

Competitive position and risks

• First-mover data advantage: every experiment compounds into a dataset competitors can't replicate quickly
• Capital intensity of lab infrastructure creates a meaningful barrier — robotics, automation, and proprietary manufacturing processes
• Key risk: other technologies (gene therapy, other nucleic acid approaches) could outperform mRNA in specific verticals even if mRNA succeeds overall
• Other mRNA companies exist; platform leapfrogging is a real threat if Moderna fails to keep investing in the underlying technology
• Management continuity and vision clarity cited as critical — the CEO held the platform thesis through years of pre-revenue development

Synthetic biology beyond therapeutics

• The same cell-programming logic applies to food, materials, and environmental remediation
• Impossible Burger's heme protein is produced by inserting the hemoglobin gene into brewer's yeast — the same cut-and-paste technique as 1978-era insulin
• Casein (the protein that makes cheese stretch) is now being produced without cows for vegan dairy
• Bioremediation: engineered organisms that break down PFAS and other persistent pollutants
• Platform companies like Ginkgo Bioworks act as the AWS layer — enabling non-biotech companies to access cell programming without in-house expertise
• Moderna's clinical-scale progress drives down the cost of the underlying tools, which benefits every adjacent application